Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530868 · ClinicalTrials.gov registry record · Phase 2
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
A Phase 2 study of Breast Cancer and Breast Neoplasm, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 7
- Study locations
NCT00530868: Completed Phase 2 study of Breast Cancer and Breast Neoplasm, sponsored by University of Alabama at Birmingham.
NCT00530868 is a Phase 2 study of Breast Cancer and Breast Neoplasm that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 75 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00530868, a Phase 2 study of Breast Cancer and Breast Neoplasm, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 7
- Study locations
Study Summary
This purpose of this trial is to show that the combination of Avastin and hormone therapy should be more effective than hormone therapy alone for the treatment of breast cancer.
Primary Outcome
Pathological complete response is defined as the absence of residual invasive tumor in the breast or axillary lymph nodes or if only residual ductal carcinoma in-situ was seen on review of the surgical specimen.
Conditions Studied
Interventions
- OTHER Letrozole (Femara)
- DRUG Letrozole; Avastin
Study Locations (7)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California, San Francisco Comprehensive Cancer Center - San Francisco
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Georgia
- Georgia Cancer Specialists - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
North Carolina
- University of of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-10-08 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
What the finished NCT00530868 record still lists
NCT00530868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Letrozole (Femara) is the first listed.
NCT00530868 lists 7 locations in 7 states (Alabama, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00530868 about?
NCT00530868 is a clinical study titled "Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer". This purpose of this trial is to show that the combination of Avastin and hormone therapy should be more effective than hormone therapy alone for the treatment of breast cancer.
What is the current status of trial NCT00530868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2007-10-08. Estimated completion is 2022-03-31.
What conditions does trial NCT00530868 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasm, Cancer of the Breast.
What interventions are being tested in trial NCT00530868?
The interventions under investigation include: Letrozole (Femara) (OTHER), Letrozole; Avastin (DRUG).
Who is sponsoring clinical trial NCT00530868?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00530868 being conducted?
This trial has 7 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00530868's enrollment target sits among peer trials
75 675th of 1224 higher than 544 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI